PROMARK

Genetic prostate cancer variants as biomarkers of disease progression

Coordinatore	ISLENSK ERFDAGREINING EHF    more  Organization address address: Sturlugata 8 city: REYKJAVIK postcode: 101 contact info Titolo: Mr. Nome: Jonsson Cognome: Frosti Email: send email Telefono: +354 570 1900 Fax: +354 570 1903
Nazionalità Coordinatore	Iceland [IS]
Sito del progetto	http://www.promark-fp7.eu/
Totale costo	4˙045˙219 €
EC contributo	2˙709˙577 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2007-A
Funding Scheme	CP-FP
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-01-01   -   2012-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	ISLENSK ERFDAGREINING EHF  Organization address address: Sturlugata 8 city: REYKJAVIK postcode: 101 contact info Titolo: Mr. Nome: Jonsson Cognome: Frosti Email: send email Telefono: +354 570 1900 Fax: +354 570 1903	IS (REYKJAVIK)	coordinator	0.00
2	INSTITUTUL DE SANATATE PUBLICA  Organization address address: Str Dr Leonte nr 1-3 city: BUCURESTI postcode: 76256 contact info Titolo: Mr. Nome: Mihai Cognome: Bogatu Email: send email Telefono: -3183599 Fax: -3183599	RO (BUCURESTI)	participant	0.00
3	STICHTING KATHOLIEKE UNIVERSITEIT  Organization address address: GEERT GROOTEPLEIN NOORD 9 city: NIJMEGEN postcode: 6525 EZ contact info Titolo: Mr. Nome: Fons Cognome: Verstralen Email: send email Telefono: +31 24 3616336 Fax: +31 24 3610191	NL (NIJMEGEN)	participant	0.00
4	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE  Organization address address: The Old Schools, Trinity Lane city: CAMBRIDGE postcode: CB2 1TN contact info Titolo: Ms. Nome: Dawn Cognome: Barker Email: send email Telefono: +44 (0) 1223 333543 Fax: +44 (0) 1223 332988	UK (CAMBRIDGE)	participant	0.00
5	UNIVERSITATEA DE MEDICINA SI FARMACIE'CAROL DAVILA' DIN BUCURESTI  Organization address address: Dionisie Lupu 37 city: BUCHAREST postcode: 20021 contact info Titolo: Ms. Nome: Ioana Cognome: Ciocan Email: send email Telefono: 4021318073 Fax: 40213180729	RO (BUCHAREST)	participant	0.00
6	UNIVERSITY COLLEGE LONDON  Organization address address: GOWER STREET city: LONDON postcode: WC1E 6BT contact info Titolo: Mr. Nome: Kent Cognome: Lee Email: send email Telefono: +44 2076796296 Fax: +44 2076796502	UK (LONDON)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Prostate cancer is the most common cancer in males in Europe, causing over 87,000 deaths in 2006. Early diagnosis and treatment are key factors in determining survival but screening methods based on the commonly-used PSA blood test have low specificity and result in excessive treatment of localized lesions that might never progress to symptomatic cancer. Biomarkers that help determine which of the early stage tumors will remain confined to the prostate and which will progress to an invasive, aggressive form of the disease are urgently needed. Using genome-wide association analysis, we identified 4 distinct common genetic variants that increase the risk of prostate cancer, some of which may have a stronger association with severe disease. Furthermore, by comparing the genotypes of patients with aggressive disease to genotypes of those with a more indolent form, we have identified a large number of candiate markers of disease severity. Here, we plan to take all these inherited variants and test the hypothesis that they can serve as biomarkers for prostate cancer prognosis and outcome. In addition, we have selected two of these variants for genomic and functional studies. Specifically, we will 1. Collect DNA and clinical data from over 8000 prostate cancer cases in four European populations (Iceland, the Netherlands, Romania, UK) 2. Test the utility of inherited prostate cancer risk variants as biomarkers of disease severity, progression and outcome 3. Start dissecting the biological mechanisms that cause increased prostate cancer risk The expected outcome of the project is a) A new prognostic test that predicts clinical outcomes for localized prostate cancer more accurately than existing methods. b) Documentation of the association of genetic risk variants to clinical parameters and outcomes. c) Increased understanding of carcinogenesis of the prostate which may lead to the identification of additional biomarkers or therapeutic targets.'